Lori Anne Kunkel
CIK 1536368 · Acting-Chief Medical Officer · last filed 2026-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.59M
Companies
6
Total Filings
48
Lifetime Open-Market Net
-$10.11M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMRA | Director | 51,884 | $17.02 | $883.0K | -$345.4K | 5 | 2026-06-09 |
| ORIC | Director | 84,200 | $8.27 | $696.3K | $0 | 11 | 2026-01-06 |
| NRIX | Director | 0 | $16.95 | $0 | $0 | 6 | 2025-05-19 |
| CRIS | Director | 22,200 | $0.42 | $9.3K | -$15.6K | 8 | 2022-01-31 |
| Forte Biosciences, Inc. (TOCA) Delisted | Acting-Chief Medical Officer | — | — | — | $0 | 4 | 2019-10-04 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 500 | — | — | -$9.75M | 10 | 2019-02-15 |
Recent Filings · Page 4 of 5
48 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-01-23 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2018-10-03 | Loxo Oncology, Inc. (LOXO) Delisted | Mixed | — | -$833.6K | EDGAR |
| 2018-06-25 | Forte Biosciences, Inc. (TOCA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-18 | Loxo Oncology, Inc. (LOXO) Delisted | Mixed | −6,840 | -$6.84M | EDGAR |
| 2018-06-14 | Loxo Oncology, Inc. (LOXO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-04-24 | Loxo Oncology, Inc. (LOXO) Delisted | Sell (S) | −5,000 | -$663.4K | EDGAR |
| 2018-01-24 | CRIS | Grant (A) | +185,000 | $0 | EDGAR |
| 2017-11-06 | Loxo Oncology, Inc. (LOXO) Delisted | Sell (S) | −5,000 | -$424.6K | EDGAR |
| 2017-08-23 | Loxo Oncology, Inc. (LOXO) Delisted | Sell (S) | −10,000 | -$751.7K | EDGAR |
| 2017-06-23 | Loxo Oncology, Inc. (LOXO) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.